Impedimed Limited

Bell Potter Analyst Maintains Buy Rating on Impedimed Limited

Storey Recommends Buying Impedimed Limited

Analyst Recommends Strong Buy on Impedimed Limited Stock

Bell Potter's Martyn Jacobs maintains a Buy rating for Impedimed Limited (IPDQF) with a price target of A$0.07. Jacobs, who covers the Healthcare sector, has an average return of -20.1% and an 11.01% success rate on recommended stocks. The analyst consensus for Impedimed Limited is a Moderate Buy with an average price target of $0.07.

Tip Ranks

Bell Potter Sticks to Its Buy Rating for Impedimed Limited (IPDQF)

Impedimed Limited (AU:IPD) announced that director Andrew Grant increased his shareholding by acquiring 98,347 ordinary shares, using 15% of his director fees for Q3 2025. This strategic move aligns his interests with the company's performance, potentially boosting stakeholder confidence. The latest analyst rating for AU:IPD is a Buy with a price target of A$0.13. ImpediMed specializes in non-invasive medical devices, focusing on fluid status and tissue composition measurement.

ImpediMed Director Increases Shareholding in Strategic Move

Morgans analyst Scott Power has maintained a Buy rating on Impedimed Limited (IPDQF) with a price target of A$0.13, while the shares closed at A$0.04. Power has an average return of -1.5% and a 41.18% success rate. Additionally, Canaccord Genuity's Shane Storey also issued a Buy rating on October 31, but TR | OpenAI reiterated a Hold rating on the same day.

Impedimed Limited (IPDQF) Receives a Buy from Morgans

Impedimed Limited has issued 438,223 ordinary shares to its non-executive directors as part of the Non-Executive Director Share Plan, covering 30% of director fees for the quarter ending September 30, 2025. This initiative aims to align directors' interests with shareholders, potentially enhancing market perception and stakeholder confidence. The current analyst rating for Impedimed Limited (AU:IPD) is a Buy, with a price target of A$0.07. The company operates in the medical technology sector, focusing on non-invasive medical devices for fluid status assessment.

Impedimed Limited Issues Shares to Non-Executive Directors

Storey covers the Healthcare sector, focusing on stocks such as Somnomed Limited, Impedimed Limited, and CSL. According to TipRanks, Storey has an average return of 9.0% and a 52.36% success rate on recommended stocks. Currently, the analyst consensus on Impedimed Limited is a Strong Buy with an average price target of $0.07.

Canaccord Genuity Sticks to Their Buy Rating for Impedimed Limited (IPDQF)

Impedimed Limited's earnings call revealed mixed sentiments, celebrating a 33% year-on-year revenue growth to $3.6 million and increased reimbursement coverage for its BIS technology. However, challenges included an 11% decline in cash receipts, underwhelming U.S. sales, and concerns over operating cash flow sustainability. The company remains optimistic about future growth, particularly in heart failure and body composition markets, supported by a cash balance of $23 million. Despite hurdles, Impedimed aims for strategic expansions and financial discipline to enhance revenue.

Impedimed Limited’s Earnings Call: Mixed Sentiments and Strategic Insights

Shapiro covers the Healthcare sector, focusing on stocks such as PYC Therapeutics Limited, Mayne Pharma Group, and Cogstate Ltd. According to TipRanks, Shapiro has an average return of -9.1% and a 33.77% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Impedimed Limited with a $0.07 average price target.

Canaccord Genuity Reaffirms Their Buy Rating on Impedimed Limited (IPDQF)

Impedimed Limited (AU:IPD) announced that director Christine Emmanuel-Donnelly has increased her shareholding by acquiring 306,446 ordinary shares, bringing her total to 1,736,255 shares in the Donnelly Superannuation Fund. This on-market trade suggests confidence in the company's future. The latest analyst rating for Impedimed stock is a Buy with a price target of A$0.20. Impedimed operates in the medical technology sector, focusing on non-invasive solutions for fluid status and tissue composition management.

Impedimed Director Increases Shareholding in Company

Impedimed Limited (AU:IPD) has announced the issuance of 815,481 fully paid ordinary shares to its executives as part of their remuneration for the quarter ended March 31, 2025. This action is part of the company’s Executive Share Plan, aimed at aligning executive compensation with company performance. Impedimed operates in the medical technology sector, focusing on innovative solutions for fluid status and tissue composition measurement. The company’s current market cap is $44.05M, with a year-to-date price performance of -50.0%.

Impedimed Issues Shares to Executives Under Remuneration Plan

Impedimed Limited (AU:IPD) has announced a proposed issue of 12,491,870 warrants to strengthen its financial position and enhance market competitiveness in the medical technology sector. The company focuses on developing non-invasive medical devices for fluid status assessment and body composition, serving healthcare areas like oncology and heart failure management. Currently, Impedimed has a market cap of $64.61M and a year-to-date price performance of -10.0%.